Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: VikingWarrior who wrote (1424)	12/19/2006 12:40:26 AM
From: JMarcus	Respond to of 1494

Dave, my emended version of the notes mentions that Paul talked about possibly doing a PIPE or monetizing the income stream from the Namenda royalties as possible ways of raising money in the interim. Paul indicated that there were several alternatives available to the company. My impression is that he would only raise enough money to get the company through the date when the interim analysis -- a binary event -- would be announced. He appears to believe that he can quickly close a deal for the European rights to Viprinex if the interim analysis has good results. The message to stockholders is that the company will keep the dilution to a minimum, raising no more money than is necessary to get to the release of the interim results. Marc